Pharma BD Deal Intelligence
A $1.4 billion acquisition that gave Astellas zolbetuximab (then IMAB362), the claudin 18.2-targeting antibody that became a validated gastric cancer therapy, plus Ganymed's oncology antibody pipeline—reinforcing Astellas' oncology push years before the drug's eventual approval.
Astellas acquired Ganymed for $1.4B for oncology.
Astellas to acquire Ganymed for EUR 422M upfront plus up to EUR 860M milestones for IMAB362.
Reports the FDA's class-first approval of Vyloy (zolbetuximab) for CLDN18.2-positive HER2-negative locally advanced/metastatic gastric and GEJ adenocarcinoma,…
Source summaries from our enrichment pipeline; follow links for originals.
All 14 sources with sentiment breakdown →
Astellas Pharma acquired Ganymed Pharmaceuticals for EUR 422 million upfront plus up to EUR 860 million in milestones (up to roughly $1.4 billion total), gaining IMAB362 (claudin 18.2-targeting antibody, later zolbetuximab) and Ganymed's broader oncology antibody pipeline. The deal furthered Astellas' oncology focus and closed December 20, 2016.
27K US cases/yr
Gastric and GEJ adenocarcinomas are aggressive upper-GI cancers, often diagnosed at advanced stage with poor survival. Claudin 18.2 is a tight-junction protein normally restricted to gastric mucosa but aberrantly retained in roughly 38% of advanced gastric/GEJ tumors at the ≥75% threshold, making it an attractive tumor-selective target for antibody therapy.
At deal time (Oct 2016), the first-line advanced gastric/GEJ standard of care was platinum-fluoropyrimidine chemotherapy plus trastuzumab for the ~20% HER2-positive subset (Herceptin, Roche). Ramucirumab (Cyramza, Lilly) had second-line approval. Checkpoint inhibitors had not yet entered first-line gastric care (Keytruda KEYNOTE-590 read out 2020; Opdivo CheckMate-649 in 2020). The Phase 2b FAST trial of zolbetuximab plus EOX showed near-doubling of OS (13.2 vs 8.4 months, HR 0.51) and PFS (7.9 vs 4.8 months) in CLDN18.2-high patients, which 'stole the show at ASCO' per FierceBiotech and underwrote Astellas's $1.4B Ganymed buyout. Pivotal Phase 3 SPOTLIGHT (mFOLFOX6) and GLOW (CAPOX) confirmed OS/PFS benefit, leading to Vyloy approvals in Japan (Mar 2024), EU (Sep 2024), and US (Oct 2024) after an initial FDA CRL on third-party manufacturing. The deal established a new biomarker-defined first-line gastric segment; competitors include AstraZeneca/Gilead's CLDN18.2 ADC AZD0901 (rilvegostomig partnership, Phase 3 GEMINI-Gastric), Innovent's IBI389, and a wave of CLDN18.2 CAR-Ts. A subsequent Vyloy failure in pancreatic cancer capped indication expansion ambitions.
27K US cases/yr · $3.8B Global Gastric Cancer Therapeutics (2016) · ~6% 5-Year Metastatic Gastric Survival
Gastric and GEJ cancers have high mortality and limited options. Ganymed's zolbetuximab targeted Claudin 18.2, a tight junction protein highly expressed in gastric tumors.
Zolbetuximab succeeded in Phase III (SPOTLIGHT, GLOW). Astellas received FDA approval for Vyloy (zolbetuximab) in 2024.
Astellas completed $1.4B acquisition of Ganymed, gaining zolbetuximab, anti-CLDN18.2 antibody for gastric and GEJ cancers.
FDA approved Vyloy as first CLDN18.2-targeted therapy for gastric/GEJ adenocarcinoma after SPOTLIGHT and GLOW Phase 3 successes.
Zolbetuximab (Vyloy) achieved FDA approval as first-in-class therapy, validating $1.4B investment. Launch trajectory and peak sales will determine final ROI.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Astellas Pharma Inc. / Ganymed Pharmaceuticals (this deal) | 2016 | $1.4B | 81 |
| Astellas Pharma Inc. / Seagen Inc. | 2009 | $4.5B | 95 |
| Astellas Pharma Inc. / Sangamo Therapeutics, Inc. | 2026 | $50M | 63 |
| Astellas Pharma Inc. / Ogeda SA | 2017 | $850M | 59 |
| Astellas Pharma Inc. / Ocata Therapeutics, Inc. | 2015 | $379M | 41 |
| Astellas Pharma Inc. / Optimer Pharmaceuticals, Inc. | 2012 | $90M | 38 |
| Astellas Pharma Inc. / OSI Pharmaceuticals | 2010 | $4.0B | 33 |
← Browse all deals · How we score deals
More: 2016 deals · Astellas Pharma Inc. deals · Oncology deals